Valneva (VALN) has released an update.
Valneva SE, a specialty vaccine company, has strategically partnered with LimmaTech Biologics AG to accelerate the advancement of a leading Shigella vaccine candidate, S4V, aimed at addressing the high unmet medical need for shigellosis prevention. Valneva has gained exclusive global licensing rights and will oversee future development and potential commercialization, while LimmaTech will receive an upfront payment plus eligibility for future milestones and royalties. This collaboration aligns with Valneva’s objective to have a new R&D program in Phase 3 by 2027, potentially offering first-in-class vaccine solutions for endemic regions and international travelers.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
